Reversal of Tamoxifen Resistance of Human Breast Carcinomas In Vivo by Neutralizing Antibodies to Transforming Growth Factor-
Open Access
- 6 January 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (1) , 46-53
- https://doi.org/10.1093/jnci/91.1.46
Abstract
BACKGROUND: Overexpression of transforming growth factor (TGF)-β has been reported in human breast carcinomas resistant to antiestrogen tamoxifen, but the role of TGF-β in this resistant phenotype is unclear. We investigated whether inhibition of TGF-β2, which is overexpressed in LCC2 tamoxifen-resistant human breast cancer cells, could modify antiestrogen resistance. METHODS: TGF-β2 expression was evaluated in LCC2 cells and tamoxifen-sensitive LCC1 cells by northern blot analysis. Secreted TGF-β activity was quantified by use of an 125 I-TGF-β competitive radioreceptor assay. Sensitivity to tamoxifen was measured in a soft agarose colony-forming assay and in a xenograft model in nude and beige/nude mice. Natural killer (NK) cell cytotoxicity was measured by 51 Cr release from LCC1 and LCC2 cell targets coincubated with human peripheral blood mononuclear cells. Decrease in TGF-β2 expression in LCC2 cells was achieved by treatment with antisense oligodeoxynucleotides and confirmed by TGF-β2 immunoblot analysis. RESULTS AND CONCLUSIONS: The proliferative response of LCC2 cells to tamoxifen in vitro was not altered by TGF-β neutralizing antibodies. However, established LCC2 tumors in nude mice treated with tamoxifen plus TGF-β antibodies failed to grow, whereas tumors treated with tamoxifen plus a control antibody continued to proliferate. This reversal of tamoxifen resistance by TGF-β antibodies did not occur in beige/nude mice, which lack NK-cell function, suggesting that immune mechanisms may be involved in the antitumor effects of tamoxifen. Antisense TGF-β2 oligodeoxynucleotides enhanced the NK sensitivity of LCC2 cells in the presence of tamoxifen. Finally, LCC1 tumors were markedly more sensitive to tamoxifen in NK-active than in NK-deficient mice. IMPLICATIONS: These data suggest that host NK function mediates, in part, the antitumor effect of tamoxifen and that TGF-β2 may abrogate this mechanism, thus contributing to tamoxifen resistance.Keywords
This publication has 32 references indexed in Scilit:
- Complex role of tumor cell transforming growth factor (TGF)-βs on breast carcinoma progressionJournal of Mammary Gland Biology and Neoplasia, 1996
- Multiple forms of TGF-β1 in breast tissues: A biologically active form of the small latent complex of TGF-β1European Journal Of Cancer, 1996
- Human breast cancer cell line xenografts as models of breast cancer — The immunobiologies of recipient mice and the characteristics of several tumorigenic cell linesBreast Cancer Research and Treatment, 1996
- Sudden tumour regression with enhanced natural killer cell accumulation in a patient with stage IV breast cancerEuropean Journal Of Cancer, 1994
- Tamoxifen resistance in breast cancerCritical Reviews in Oncology/Hematology, 1993
- Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory diseaseNature, 1992
- Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancerBritish Journal of Cancer, 1991
- Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytesCellular Immunology, 1987
- In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen)European Journal of Cancer and Clinical Oncology, 1984